Nitric oxide-dependent renal vasodilatation is not altered in rat with rHuEpo-induced hypertension

Kidney and Blood Pressure Research

Volumn 22, Issue 3, 1999, Pages 140-145

  Migliori, M ^b   Taccola, D ^b   Panichi, Vincenzo ^a   De Pietro, S ^b   Andreini, B ^b   Di Benedetto, A ^b   Filippi, C ^b   Palla, R ^b   Giovannini, L ^b  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

Acetylcholine; Endothelium; Erythropoietin; Hypertension; L NAME; Nitric oxide; Sodium nitroprusside

Indexed keywords

ACETYLCHOLINE; HEMOGLOBIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HYPERTENSION; KIDNEY CIRCULATION; KIDNEY FAILURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

EID: 0032805265     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025920     Document Type: Article

References (37)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987;316:73-78
2. Raine AEG: Hypertension, blood viscosity and cardiovascular morbidity in renal failure: Implication of erythropoietin therapy. Lancet 1988;i:97-100.
3. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW: Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 1990;3:947-955.
4. Kulzer P, Schaefer RM, Krahn R, Schaefer L, Heidland A: Effectiveness and safety of recumbinant human erythropoietin in the treatment of anemia of chronic renal failure in non dialysis patients. Int J Artif Organs 1994;17: 192-202.
5. MacDougall IC, Davies ME, Hutton RD, Coles GA, Williams JD: Rheological studies during treatment of renal anemia with recombinant human erythropoietin. Br J Haematol 1991;77:550-558.
6. Nonnast-Daniel B, Schaffer J, Frei U: Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin. Contrib Nephrol. Basel, Karger, 1989, vol 76, pp 283-291.
7. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, Eggena MP, Clegg K, Nakhoul F, Lee DBN: Influence of recombinant human erythropoietin on blood pressure and tissue renin angiotensin system. Am J Physiol 1991;261:E642-E646.
8. Fritschka E, Neumayer HH, Seddighi S, Thiede HM, Distler A, Philipp TH: Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis. Br J Clin Pharmacol 1990; 30:S135-S138.
9. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC: Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 1992;20 (Suppl 12):25-28.
10. Carlini RG, Obialo C, Rothstein M: Intravenous erythropoietin administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 1993; 6:103-107.
11. Tsukada H, Ishimitsu T, Ogawa Y, Sugimoto T, Yagi E: Direct vasopressor effect of erythropoietin in genetically hypertensive rats. Life Sci 1993;52:1425-1434.
12. Del Castillo D, Raij L, Shultz PJ, Tolins JP: The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrol Dial Transplant 1995;10:505-508.
13. Tsukahara H, Hiraoka M, Hori C, Hata I, Okada T, Geiyo F, Sudo M: Chronic erythropoietin tretament enhances endogenous nitric oxide production in rats. Scand J Clin Lab Invest 1997;57:487-493.
14. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM: Vascular mechanism of cyclosporin-induced hypertension in the rat. J Clin Invest 1994;93:2244-2250.
15. Takahashi S, Yanai M, Okada K: Recombinant human erythropoietin has no direct or strong vasoconstrictor effects in vivo and in vitro. Nephrol Dial Transplant 1995;10:815-820.
16. Bagnis C, Deray G, Dubois M, Jaquiaud C, Bitker MO, Jacobs C: Prevention of acute cyclosporine nephrotoxicity by verapamil and atrial natriuretic factor in the rat. Nephrol Dial Transplant 1994;9:1143-1148.
17. Schurek HJ, Brecht JP, Lohfert H, Hierholzer K: The basic requirement for the function of the isolated cell free perfused rat kidney. Pflügers Arch 1975;354:349-365.
18. Maack T: Renal clearance and isolated kidney perfusion technique. Kidney Int 1986;30:142-151.
19. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. J Clin Invest 1993;91:642-650
20. 15N-nitrate in biological fluids. Anal Biochem 1982;126:131-138.
21. Granger DL, Hibbs JB, Perfect JR, Durack DT: Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest 1990;85:264-273.
22. Kaupke CJ, Kim S, Vaziri ND: Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994;4: 1874-1878.
23. Gill ML, Anderton JL: Erythropoietin-induced hypertension without raising hematocrit. Nephrol Dial Transplant 1993;8:1264-1266.
24. Susic D, Mandal AK, Kentera D: Hemodynamic effects of chronic alteration in hematocrit in spontaneously hypertensive rats. Hypertension 1984;6:262-266.
25. Muntzel M, Hannedouche T, Lacour B, Drüeke TB: Erythropoietin increases blood pressure in normotensive and hypertensive rats. Nephron 1993;65:601-604.
26. Brunet P, Lorec AM, Leonetti F, et al: Plasma endothelin in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1994;9:650-654.
27. Fluck RJ, Roger SD, Mc Mahon AC, Raine AEG: Modulation of platelet cytosolic calcium during erythropoietin therapy in uraemia. Nephrol Dial Transpl 1994;9:1109-1114.
28. Zhou XJ, Pandian D, Wang XQ, Vaziri ND: Erythropoietin-induced hypertension in the rat is not mediated by alteration of plasma endothelin, vasopressin, or atrial natriuretic peptide levels. J Am Soc Nephrol 1997;8:901-905.
29. Lebel M, Kingma I, Grose JH, Langlois S: Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 1998;9:97-104.
30. Raine AEG, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18:76-83.
31. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM: Abnormal renal hemodynamic response to reduce renal perfusion pressure in diabetic rats: Role of NO. Am J Physiol 1993;265:F886-F895.
32. Wong GKT, Mardsen PA: Nitric oxide synthase: Regulation in disease. Nephrol Dial Transplant 1996;11:215-220.
33. Calver A, Collier J, Moncada S, Vallance P: Effect of local intra-arterial N-monomethyl-L-arginine in patients with hypertension: The nitric oxide dilator mechanism appears abnormal. J Hypertens 1992;10:1025-1031.
34. Moncada S, Palmer RM: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.
35. Calver A, Collier J, Vallance P. Nitric oxide and cardiovascular control. Exp Physiol 1993;98:303-326.
36. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC: Hypertension in mice lacking the gene encoding for endothelial nitric oxide synthase. Nature 1995;377:239-241.
37. Vaziri ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, Purdy RE: Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 1996;271:E113-E122.